Fortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative Medicine Advanced Therapy Designation for the Treatment of Traumatic Brain Injury Nov 08, 2017
Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting Nov 01, 2017
Mustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting Nov 01, 2017
Fortress Biotech Announces Subsidiary Data to Be Presented at 59th American Society of Hematology Annual Meeting Nov 01, 2017
Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain Oct 31, 2017
Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma Oct 11, 2017
